Business Wire

SEOUL-SEMICONDUCTOR

Share
Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Selected by Product Innovation Brand biOrb

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED technology, announced that its SunLike Series natural spectrum LEDs, which implement light that closely matches the spectrum of sunlight, has been adopted by biOrb for its innovative new Vivariums.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211109005201/en/

biOrb Vivariums (from Oase) have created an innovative and original approach which allows reptile enthusiasts to recreate their own small biome. Recent research is showing that one of the most important aspects in recreating a natural habitat is the quality of the light used, after millions of years of evolution, full spectrum light is a major part of the animal's welfare, until now, this has been impossible to achieve. But now with Sunlike reptiles and plants are thriving and the hobbyist can see their world as nature intended, in all its vibrancy.

With SunLike Series natural spectrum LEDs, the fixtures are designed to bring out the natural colour tones of objects achieving a lower blue light peak, similar to the sunlight spectral curve, which enables the reduction of scattered reflection and glare and it also provides healthy and comfortable light, improving the environment for living and displaying colors and textures more accurately with CRI 97 and TM30 = 100.

There has been a significant increase in research activity on the relationship between light and human and animal bio-functions, including a recent scientific study focused on the effects of light spectrum on sleep quality, visual comfort, overall well-being, and daytime alertness; encompassing the interaction of both visual and non-visual light on humans, plants and animals. The study, published in the Journal of Lighting & Research Technology on March 24, 2019, found “evidence that a daylight [natural spectrum] LED solution has beneficial effects on visual comfort, daytime alertness, mood, and sleep intensity in healthy volunteers.”

“Seoul Semiconductor’s SunLike Series natural spectrum LEDs have two beneficial effects in contrast to conventional LEDs for animals. There is the right amount of cyan 490nm wavelength to stimulate them during the day and there is no blue energy in the night to calm and prepare the animals to sleep like the real day/night cycle” said Oliver Schaefer Europe Executive Vice President of Seoul Semiconductor. “We have more and more customers interested in the SunLike technology as thanks to scientists we are discovering new applications every day” added him.

SunLike Series LEDs are an advanced technology that has achieved the highest level of eye safety certification from the International Commission on Illumination as a safe light source with no photo-biological risks.

Introduced in June 2017, the SunLike Series natural spectrum LEDs are an advanced light source that combine the latest optical and compound semiconductor technology of Seoul Semiconductor with Toshiba Materials’ TRI-R® technology. TRI-R, supported by Toshiba Materials, finds in the definition “The light closest to the sun for human well-being” its original concept. The sun light spectrum is developed by the same company and can be reproduced by a white LED light source technology. TRI-R is a registered trademark by the Toshiba Materials Co., LTD.

About biOrb

Since 1999 biOrb has stood for innovation. Initially designing easy-to-own aquariums and more latterly, Terrariums and now Vivariums.

Today, biOrb is owned by German manufacturer OASE. The OASE name stands for spectacular fountains and “state of the art” equipment and services. Founded in 1949, OASE is now the market leader in the fountain technology industry. Our innovative products are designed for long life with maximized reliability as well as ease of maintenance and our support & service are the best in the industry. Headquartered in Germany, OASE understands the importance of a local presence to customers. We believe it is important to support our customers wherever they are located. With 13 subsidiaries in Europe, Asia and the US and a network of certified local partners we provide our customers fast, reliable, and efficient after Sales Services in their native language whenever and wherever they are needed.

About Seoul Semiconductor

Seoul Semiconductor develops and commercializes LEDs for automotive, general illumination, specialty lighting, and backlighting markets. As the second-largest LED manufacturer globally excluding the captive market, Seoul Semiconductor holds more than 14,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike – delivering the world’s best light quality in a next-generation LED enabling human-centric lighting optimized for circadian rhythms; WICOP – a simpler structured package-free LED which provides market leading color uniformity and cost savings at the fixture level, providing high lumen density and design flexibility; NanoDriver Series – the world’s smallest 24W DC LED drivers; Acrich, the world's first high-voltage AC-driven LED technology developed in 2005, including all AC LED-related technologies from chip to module and circuit fabrication, and nPola, a new LED product based on GaN-substrate technology that achieves more than ten times the output of conventional LEDs. UCD constitutes a high color gamut display which delivers more than 90% NTSC. For more information, please visit www.seoulsemicon.com/en .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye